• Journal of Chest Surgery
• /
• 제19권3호
• /
• pp.484-488
• /
• 1986

Mucoepidermoid carcinoma is one of bronchial adenoma which arising from submucosal gland or mucosal gland of lower respiratory tract. The symptoms of the tumor were produced by bronchial irritation and bronchial obstruction such as coughing, pneumonitis, and atelectasis. The malignancy potency of this tumor was determined by histologic pattern but high grade malignancy was uncommon and so distant metastasis was rare. Three treatment modality such as surgery, radiotherapy, chemotherapy were used for treatment but radiotherapy and chemotherapy were lesser effective than surgery. So Early and radical resection of tumor was recommended. Here we report one case of mucoepidermoid carcinoma which treated with radical resection.

• IMMUNE NETWORK
• /
• 제11권4호
• /
• pp.210-215
• /
• 2011

It is already known that high concentration of vitamin C induces apoptosis on tumor cells. However, there is no report regarding the function of vitamin C on the modulation of immune susceptibility of cancer. Therefore, we investigated whether vitamin C can modulate immune susceptibility of tumor cells, especially on the induction of Fas-mediated apoptosis. First, the optimal concentration of vitamin C, which cannot induce damages on tumor cells for 36 hrs. We found that 2 mM of vitamin C did not show harmful effect. In addition, the optimal concentration of agonistic anti-Fas Abs for 18 hrs was examined. As a result, 400 ng/ml of agonistic anti-Fas Abs did not induce apoptosis on tumor cells. Next, we tried to find the effect of 2 mM of vitamin C on the modulation of the susceptibility to agonistic anti-Fas Abs. When tumor cells were cultured with 400 ng/ml of agonistic anti-Fas Abs for 18 hrs, after pre-treatment with 2 mM of vitamin C for 24 hrs, viability of cells was decreased. Interestingly, we found that the expression of Fas (CD95) and MHC class I was increased by the treatment of vitamin C. Taken together, vitamin C increases the susceptibility of tumor cells to anti-Fas Abs and the expression of Fas (CD95) and MHC class I on tumor cells.

• The Korean Journal of Physiology and Pharmacology
• /
• 제20권3호
• /
• pp.261-268
• /
• 2016

$Foxp3^+$ $CD25^+CD4^+$ regulatory T (Treg) cells are crucial for the maintenance of immunological self-tolerance and are abundant in tumors. Most of these cells are chemo-attracted to tumor tissues and suppress anti-tumor responses inside the tumor. Currently, several cancer immunotherapies targeting Treg cells are being clinically tested. Cisplatin is one of the most potent chemotherapy drugs widely used for cancer treatment. While cisplatin is a powerful drug for the treatment of multiple cancers, there are obstacles that limit its use, such as renal dysfunction and the development of cisplatin-resistant cancer cells after its use. To minimize these barriers, combinatorial therapies of cisplatin with other drugs have been developed and have proven to be more effective to treat cancer. In the present study, we evaluated the effect of the combination therapy using methyl gallate with cisplatin in EL4 murine lymphoma bearing C57BL/6 mice. The combinatorial therapy of methyl gallate and cisplatin showed stronger anti-cancer effects than methyl gallate or cisplatin as single treatments. In Treg cell-depleted mice, however, the effect of methyl gallate vanished. It was found that methyl gallate treatment inhibited Treg cell migration into the tumor regardless of cisplatin treatment. Additionally, in both the normal and cisplatin-treated tumor-bearing mice, there was no renal toxicity attributed to methyl gallate treatment. These findings suggest that methyl gallate treatment could be useful as an adjuvant method accompanied with cisplatin therapy.

• 대한두경부종양학회지
• /
• 제9권1호
• /
• pp.98-101
• /
• 1993

Surgery has been known to be traditional treatment modality for the malignant salivary gland tumor, the tumors being considered as radioresistant. However, reviews of the literature have shown a high recurrence rate, especially in advanced and/or high grade tumors. The retrospective data suggests that conservative surgery with adjunctive radiation therapy is justified in view of the enhanced locoregional control. In inoperable and recurrent tumor, definitive radiotherapy can achieve $30{\sim}40%$ of average 5 year survival rate, but in early stage, local control and survival rate could be raised more than 80%. This results shown to be aggressive radiotherapy can replace surgical management for the selected cases of small sized tumor. Neutron therapy is another option for curative treatment of malignant salivary gland tumors.

• Journal of Chest Surgery
• /
• 제7권1호
• /
• pp.37-46
• /
• 1974

52 cases of metastatic lung tumor, including 22 [42.3%] choriocarcinoma., 13[25%] liver cancer, 6 [7.5%] stomach cancer, 2 bone tumor, etc, were reviewed at Busan National University Hospital, during a 5 year period ending with 1974. The age distribution of metastatic lung tumor were same in second decade to 5th decade. The most common appearances of roentgenograms of metastatic lung tumor were that of multinodular [42.3%], diffuse acinar [21.1%],infiltrative or pneumonic[21.1%], solitary lesion [9.6%] and diffuse micronodular [5.7%]. The metastatic lesions originated from choriocarcinoma revealed multinodular and acinar in roentgenogram, and the lesions originated from liver and stomach cancer revealed infiltrative and acinar. In our series, the positive hilar lymph node enlargement was encountered in 12 cases, of which 4 were in liver cancer and 3 were in stomach cancer. Pleural effusion was also encountered in 5 cases, of which 3 were in liver cancer. The treatment of this series was almost conservative except of 2 cases of pulmonary resection, and the reason of this limited cases of surgical treatment was seemed due to the delayed direction of metastasis to lung beyond the proper indication of surgery.

• Journal of Chest Surgery
• /
• 제51권6호
• /
• pp.415-418
• /
• 2018

A solitary fibrous tumor (SFT) is a mesenchymal fibroblastic tumor inside the pleura, for which complete surgical resection is the standard treatment. For large SFTs, preoperative identification of tumor-feeding vessels using angiography is important for achieving complete resection without unexpected operative bleeding. Extensive adhesions can make resection difficult in a limited operative window, and pulmonary resection may be required to achieve complete SFT resection. Herein, we report successful resection of a large pleural SFT in a 39-year-old man without any complications using a 2-stage approach, in which ligation of the feeding vessels through small another operative window was the first step.

• Radiation Oncology Journal
• /
• 제26권4호
• /
• pp.263-270
• /
• 2008

목 적: 본 연구에서는 로봇 사이버나이프의 호흡추적장치($Synchrony^{TM}$ Respiratory motion tracking system)을 이용하여 방사선수술을 시행한 간 종양환자를 대상으로 치료 중 실시간 종양의 움직임을 정량적으로 측정하고 방사선 수술시 호흡추적장치의 정확성을 평가하고자 한다. 대상 및 방법: 사이버나이프 치료를 시행한 간 종양 환자 24명을 대상으로 호흡추적 장치를 이용하여 총 64회의 시술을 시행하였다. 모든 환자에서 초음파를 이용하여 간 종양 근처에 $4{\sim}6$개의 금침을 삽입하였고 치료계획용 컴퓨터 단층촬영 영상을 이용하여 치료계획을 세웠다. 매 치료 시 금침의 위치는 치료계획 시 만들어진 디지털 재구성 방사선 영상(Digitally Reconstructed Radiography; DRR)과 실시간으로 촬영되어진 방사선영상(X-ray image)으로 확인하고, 이 결과를 MTS (Motion Tracking System)을 통해 Mtsmain.log 치료파일 형식으로 저장하여 종양의 움직임을 측정하였다 또한 사이버나이프를 이용한 방사선 수술 시 호흡추적장치의 정확성은 실시간 금침의 위치와 미리 예측된 좌표 사이의 상관관계 오차(Correlation Error)로 평가하였다. 결 과: 간 종양의 직선형태 움직임은 SI (Superior-Inferior)방향으로 최대 23.5 mm, 평균 $13.9{\pm}5.5\;mm$, LR (Left-Right)방향으로 최대 3.9 mm, 평균 $1.9{\pm}0.9\;mm$, AP (Anterior-Posterior)방향으로 최대 8.3 mm, 평균 $4.9{\pm}1.9\;mm$였으며 간 종양의 회전 운동 정도는 X (Left-Right)축 회전은 최대 $3.3^{\circ}$, 평균 $2.6{\pm}1.3^{\circ}$, Y (Cranio-Caudal)축회전은 최대 $4.8^{\circ}$, 평균 $2.3{\pm}1.0^{\circ}$, Z (Anterior-Posterior)축 회전은 최대 $3.9^{\circ}$, 평균 $2.8{\pm}1.1^{\circ}$로 측정되었다. 또한 치료의 정확성을 평가하는 상관관계 오차는 평균 $1.1{\pm}0.7\;mm$였다. 결 론: 본 연구에서 방사선 수술 중 간 종양의 실시간 움직임을 정량적으로 확인할 수 있었고 로봇 사이버나이프의 호흡추적 장치를 이용한 방사선 수술의 정확성을 평가할 수 있었다 이를 토대로 간 종양의 방사선 수술이나 일반적인 방사선치료에 있어서 치료용적의 결정과 움직임에 대한 유용한 정보를 제공할 것이라 생각된다.

• 대한한의학방제학회지
• /
• 제5권1호
• /
• pp.127-145
• /
• 1997

This study was aimed to investigate the anti-tumor and immune response effect of Samyongtang(S1; this medicine represents for 'ENERGIZER'), Yangjeongjejeoktang(S2; this is the 'INTERMEDIATE METHOD' of S1 and S3) and Onbeakwon(S3; this is 'ATTACK' the disease of mass) on the experimental rats induced by Sarcoma-180 and Methotrexate. And to observed the differences S1, S2, and S3 treatment groups. Tumor weight(TW) in vivo, interleukin-2(IL-2), hemagglutinin titer(H.A), hemolysin titer(HL), rossete forming cell(RFC), delayed type hypersensitivity(DTH), and natural killer cell activity(NKCA) in vivo were measured in rats. The obtained results were summarized as follows. 1. Tumor weight was decreased in all treatment groups (S2>S3>S1) as compared with control group, but the difference was not statistically significant each treatment groups. 2. Interleukin-2 was increased in all treatment groups (S1>S2>Ss) as compared with control group, but the difference was not statistically significant each treatment groups. 3. Hemagglutinin titer was increased in all treatment groups (S1>S2>S3) as compared with control group, but the difference was not statistically significant each treatment groups. 4. Hemolysin titer was increased in all treatment groups (S1>S2>S3) as compared with control group, but the difference was not statistically significant each treatment groups. 5. Rossete forming cell(RFC) was increased in all treatment groups (S1>S2>S3) as compared with control group, but the difference was not statistically significant each treatment groups. 6. Delayed type hyperseneitivity(DTH) was increased in S1, S2 treatment groups (S1>S2) as compared with control group, but it was decreased in S3 treatment group. Therefore, S1 group was statistically significant compared with S3 groups. 7. Natural killer cell activity(NKCA) was increased in all treatment groups (S2>S3>S1) as compared with control group, but the difference was not statistically significant each treatment groups. Based on the above mentioned results, it is suggested that S1, S2 and S3 will have anti-tumor substances and enhance effect of immune response. But the differences were not statistically significant in each treatment groups, except for delayed type hypersensitivity.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제35권2호
• /
• pp.66-73
• /
• 2009

Tumor angiogenesis is a process leading to formation of blood vessels within tumors and is crucial for maintaining a supply of oxygen and nutrients to support tumor growth and metastasis. Vascular endothelial growth factor(VEGF) plays a key role in tumor angiogenesis including induction of endothelial cell proliferation, migration, survival and capillary tube formation. VEGF binds to two distinct receptors on endothelial cells. VEGFR-2 is considered to be the dominant signaling receptor for endothelial cell permeability, proliferation, and differentiation. Bevacizumab(Avastin, Genetech, USA) is a monoclonal antibody against vascular endothelial growth factor. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels. The goal of this study is to identify the anti-tumor effect of Bevacizumab(Avastin) for oral squamous cell carcinoma cell lines. Human squamous cell carcinoma cell line(HN4) was used in this study. We examined the sensitivity of HN4 cell line to Bevacizumab(Avastin) by using in vitro proliferation assays. The results were as follows. 1. In the result of MTT assay according to concentration of Bevacizumab(Avastin), antiproliferative effect for oral squamous cell carcinoma cell lines was observed. 2. The growth curve of cell line showed the gradual growth inhibition of oral squamous cell carcinoma cell lines after exposure of Bevacizumab(Avastin). 3. In the apoptotic index, groups inoculated Bevacizumab(Avastin) were higher than control groups. 4. In condition of serum starvation, VEGFR-2 did not show any detectable autophosphorylation, whereas the addition of VEGF activated the receptor. Suppression of phosphorylated VEGFR-2 and phosphorylated MAPK was observed following treatment with Bevacizumab(Avastin) in a dose-dependent manner. 5. In TEM view, dispersed nuclear membrane, scattered many cytoplasmic vacuoles and localized chromosomal margination after Bevacizumab(Avastin) treatment were observed. These findings suggest that Bevacizumab(Avastin) has the potential to inhibit MAPK pathway in proliferation of oral squamous cell carcinoma cell lines via inhibition of VEGF-dependent tumor growth.

• 동의생리병리학회지
• /
• 제21권3호
• /
• pp.736-740
• /
• 2007

Acanthopanax sessiliflorus SEEM extracts(AS) have been used to treat patient with diseases including cancer in Oriental countries. Recently, AS was known to have anti-cancer and immuno-stimulating activites. For these reasons, we investigated the effects of AS following gamma-ray irradiation on cytotoxicity for solid tumor cell line (S-180) and immune-potentiating ability such as proliferation of thymocytes and splenocytes. Finally we also investigated tumor weight and survival rate in tumor bearing mice. In our results, Treatment with AS suppressed proliferation of solid tumor cells (S-180) effectively. Treatment with AS accelerated thymocyte and splenocyte proliferation in tumor bearing mice. In addition, Treatment with AS reduced tumor weight and prolonged life of tumor bearing mice. In conclusion, we demonstrate that AS following gamma-ray irradiation is useful to treat patients with cancer, and also demonstrate that AS have both direct cytotoxic ability for cancer cells and indirect immune-stimulating action for thymocytes and splenocytes.